| 1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
|
| 2 |
Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28: 5311-5320.
|
| 3 |
Wakelee H, Zvirbule Z, De Braud F, et al. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer[J]. Clin Lung Cancer, 2017, 18: 50-59.
|
| 4 |
张 卉，张树才. 非小细胞肺癌EGFR基因靶向治疗研究进展[J]. 中国肺癌杂志，2017, 20(1): 61-65.
|
| 5 |
Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-Mainland China Subset Analysis of the PIONEER study[J]. PLoS One, 2015, 10(11): e0143515.
|
| 6 |
Lu Xu, Xin-Hua Xu, Cheng Yuan, et al. Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy[J]. Ann Transl Med, 2018, 6(20): 405.
|
| 7 |
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group[J]. Am J Clin Oncol, 1982, 5(6): 649-655.
|
| 8 |
Buccheri G1, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution[J]. Eur J Cancer, 1996, 32A(7): 1135-1141.
|
| 9 |
张百红，岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志，2016, 43(11): 845-847.
|
| 10 |
Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15: 2403-2413.
|
| 11 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 12 |
刘 鹏，杜秀婷，韦海林，等. 中国与美国恶性肿瘤的现状比较及差异分析[J]. 肿瘤预防与治疗，2017, 30(4): 299-304.
|
| 13 |
陈万青，李 贺，孙可欣，等. 2014年中国恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志，2018, 40(1): 5-13.
|
| 14 |
刘 夏，钟殿胜. 晚期非小细胞肺癌BRAF突变靶向治疗进展[J]. 中国肺癌杂志，2018, 21(8): 635-640.
|
| 15 |
中华医学会，中华医学会肿瘤学分会，中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J]. 肿瘤研究与临床，2018, 30(12): 793-824.
|
| 16 |
马 峰，史晓宇，孟 玮. EGFR野生型晚期非小细胞肺癌的治疗进展[J]. 中国肺癌杂志，2014, 17(7): 575-580.
|
| 17 |
Tanino R, Tsubata Y, Harashima N, et al. Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer[J]. Oncotarget, 2018, 9(24): 16807-16821.
|
| 18 |
Wen M, Xia J, Sun Y, et al. Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation[J]. Biologics, 2018, 12: 183-190.
|
| 19 |
Vanita Noronha, Amit Joshi, Vijay Maruti Patil, et al. Phase Ⅲ randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C)[J]. J Clin Oncol, 2019, 37(15suppl)0DOI: 10.1200/JCO.2019.37.15_suppl.9001?. |
| 20 |
Lisheng Xu, Qian Qi, Yan Zhang, et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study[J]. Lung Cancer, 2019, 133: 23-31.
|
| 21 |
Kumar R, Dubashi B, Kayal S, et al. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study[J]. Indian J Cancer, 2017, 54: 188-192.
|
| 22 |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361: 947-957.
|
| 23 |
Pirker R, Pereira JR, Szczesna A, et al. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase Ⅲ FLEX study[J]. Lung Cancer, 2012, 77: 376-382.
|
| 24 |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361: 947-957.
|
| 25 |
Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14: 953-961.
|
| 26 |
Sun JM, Lee KH, Kim SW, et al. Gefitinib versus pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial[J]. Cancer, 2012, 118: 6234-6242.
|
| 27 |
Bronte G, Franchina T, Alu M, et al. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status[J]. Oncotarget, 2016, 7: 35803-35812.
|
| 28 |
Germonpre P, Van den Wyngaert T. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer(NSCLC): Real-world effectiveness, safety and tolerability[J]. PLoS ONE, 2019, 14(4): e0215135.
|
| 29 |
Fiala O, Pesek M, Finek J, et al. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence[J]. Anticancer Res, 2013, 33: 3397-3402.
|
| 30 |
张崇国，王继荣，李 娟，等. 非小细胞肺癌EGFR突变状态不明患者化疗和靶向治疗的生存分析[J]. 中国医药导报，2018, 5: 107-112.
|